News

Date

Title

Sep 29, 2021

ILiAD Biotechnologies Reports Preliminary Data Demonstrating Pertussis Vaccine Candidate BPZE1, but Not Boostrix, Induces Functional Bactericidal Antibodies Against Pertactin Negative B. Pertussis

Oct 21, 2020

ILiAD Biotechnologies Announces Upcoming Presentation at the European Society for Paediatric Infectious Diseases 2020 Virtual Meeting

Sep 29, 2020

ILiAD Biotechnologies Reports Positive Topline Results from Phase 2b Trial for Pertussis Vaccine Candidate BPZE1

Sep 24, 2020

ILiAD Biotechnologies Announces Presentation of Positive Phase 2b Data for Next Generation Pertussis Vaccine at World Vaccine Congress

Nov 19, 2019

Dr. Cheryl Keech Joins ILiAD Biotechnologies as Chief Medical Officer and Executive VP of Clinical Research

Oct 8, 2019

ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Full Enrollment In 300-Subject Multicenter Phase 2b Clinical Trial

Jun 25, 2019

ILiAD Biotechnologies Announces First Patient Enrolled in BPZE1 Pertussis Vaccine Multicenter Phase 2b Clinical Trial

Dec 19, 2018

ILiAD Biotechnologies Secures Up to $20 million of Financing and Phase 2a BPZE1 Pertussis Vaccine Trial Initiates at Vanderbilt University Medical Center

May 15, 2018

NIAID Sponsors ILiAD Biotechnologies BPZE1 Pertussis Vaccine Phase 2a Clinical Study at Vanderbilt University

July 5, 2017

ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Key Milestones Including Positive Phase 1b Clinical Study Data

February 19, 2016

Phase 1b Clinical Trial of BPZE1 Pertussis Vaccine Completes Enrollment of Randomized Study Groups

January 8, 2014

ILiAD Biotechnologies, Inserm and Inserm Transfert SA, and Institut Pasteur de Lille Enter Scientific Collaboration and Worldwide License Agreements for Vaccine Technology


Copyright 2013-2021 ILiAD Biotechnologies